Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 9, 2013 - Issue 1
Submit an article Journal homepage
1,305
Views
25
CrossRef citations to date
0
Altmetric
Commentary

Peptide vaccines for hepatocellular carcinoma

Daisuke Nobuoka Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan; Department of Gastroenterological Surgery; Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences; Kita-ku, Okayama, Japan
,
Toshiaki Yoshikawa Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan
,
Yu Sawada Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, Japan
,
Toshiyoshi Fujiwara Department of Gastroenterological Surgery; Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences; Kita-ku, Okayama, Japan
&
Tetsuya Nakatsura Division of Cancer Immunotherapy; Research Center for Innovative Oncology; National Cancer Center Hospital East; Kashiwa, JapanCorrespondence[email protected]
Pages 210-212 | Received 23 Sep 2012, Accepted 06 Oct 2012, Published online: 01 Jan 2013

References

  • Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74 - 108; http://dx.doi.org/10.3322/canjclin.55.2.74; PMID: 15761078
  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378 - 90; http://dx.doi.org/10.1056/NEJMoa0708857; PMID: 18650514
  • Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25 - 34; http://dx.doi.org/10.1016/S1470-2045(08)70285-7; PMID: 19095497
  • Greten TF, Forner A, Korangy F, N’Kontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10:209; http://dx.doi.org/10.1186/1471-2407-10-209; PMID: 20478057
  • Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27:130 - 9; http://dx.doi.org/10.1002/hon.886; PMID: 19294626
  • Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044; PMID: 22577059
  • Filmus J. The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002; 19:319 - 23; http://dx.doi.org/10.1023/A:1025312819804; PMID: 12975611
  • Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16 - 25; http://dx.doi.org/10.1016/S0006-291X(03)00908-2; PMID: 12788060
  • Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, et al. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res 2004; 10:8630 - 40; http://dx.doi.org/10.1158/1078-0432.CCR-04-1177; PMID: 15623647
  • Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34:649 - 56; PMID: 19212669
  • Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100:1403 - 7; http://dx.doi.org/10.1111/j.1349-7006.2009.01206.x; PMID: 19496787
  • Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689 - 97; http://dx.doi.org/10.1158/1078-0432.CCR-05-2267; PMID: 16675560
  • Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int J Oncol 2008; 32:985 - 90; PMID: 18425324
  • Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, et al. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 2011; 102:918 - 25; http://dx.doi.org/10.1111/j.1349-7006.2011.01896.x; PMID: 21281401
  • Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, et al. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Cancer Sci 2011; 102:1622 - 9; http://dx.doi.org/10.1111/j.1349-7006.2011.02003.x; PMID: 21668581
  • Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009; 21:233 - 40; http://dx.doi.org/10.1016/j.coi.2009.03.002; PMID: 19304471

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.